<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zagouri, F.</style></author><author><style face="normal" font="default" size="100%">Sergentanis, T.N.</style></author><author><style face="normal" font="default" size="100%">Gazouli, M.</style></author><author><style face="normal" font="default" size="100%">Tsigginou, A.</style></author><author><style face="normal" font="default" size="100%">Dimitrakakis, C.</style></author><author><style face="normal" font="default" size="100%">Papaspyrou, I.</style></author><author><style face="normal" font="default" size="100%">Eleutherakis-Papaiakovou, E.</style></author><author><style face="normal" font="default" size="100%">Chrysikos, D.</style></author><author><style face="normal" font="default" size="100%">Theodoropoulos, G.</style></author><author><style face="normal" font="default" size="100%">Zografos, G.C.</style></author><author><style face="normal" font="default" size="100%">Antsaklis, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, A.M.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study.</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular biology reports</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84875811243&amp;partnerID=40&amp;md5=db55d0f4b17ebf0a172fd64913cb2cb8</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">39</style></volume><pages><style face="normal" font="default" size="100%">10873 - 10879</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">This case control study aims to investigate the role of HSP90 Gln488His (C &gt; G), HSP70-2 P1/P2, HIF-1 alpha C1772T and HSPA8 intronic 1541-1542delGT polymorphisms as potential risk factors and/or prognostic markers for breast cancer. 113 consecutive incident cases of histologically confirmed ductal breast cancer and 124 healthy cases were recruited. The above mentioned polymorphisms were genotyped; multivariate logistic regression was performed. HSP90 GG (His/His) genotype was associated with elevated breast cancer risk. Similarly, the allele dose-response model pointed to increase in breast cancer risk per G allele. HSP70-2 P1/P2, HSPA8 intronic 1541-1542delGT and HIF-1 alpha polymorphisms were not associated with breast cancer risk, as evidenced by the dose-response allele models. The positive association between HSP90 G allele and breast cancer risk seemed to pertain to both premenopausal and postmenopausal women. With respect to survival analysis, none of the aforementioned polymorphisms was associated with either disease-free survival or overall survival. HSP90α Gln488His polymorphism seems to be a risk factor for breast cancer. On the other hand, our study did not point to excess risk conferred by HSPA8 1541-1542delGT, Hsp70-2 P1/P2 and HIF-1α C1772T.</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><notes><style face="normal" font="default" size="100%">Cited By :16Export Date: 21 February 2017</style></notes></record></records></xml>